Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 June 2025 | Story Martinette Brits | Photo Supplied
South Campus
The University of the Free State’s South Campus is set to become the hub of a pioneering veterinary science programme — only the second of its kind in South Africa.

The University of the Free State (UFS) is advancing plans to establish a new veterinary science programme – set to become only the second of its kind in South Africa. This initiative includes the development of a professionally accredited Bachelor of Veterinary Science (BVSc) degree and a state-of-the-art veterinary teaching hospital on the South Campus in Bloemfontein. It will also leverage the university’s Paradys Experimental Farm, home to advanced agricultural infrastructure and established production animal herds.

“The UFS is planning a new veterinary programme, strategically supported by the unique infrastructure and resources of its South Campus,” says Prof Johan van Niekerk, Vice-Dean of Agriculture in the Faculty of Natural and Agricultural Sciences. “Located in close proximity to the Paradys Experimental Farm, the campus provides an ideal environment for practical veterinary training. The farm’s real-world livestock systems will offer students invaluable experiential learning opportunities in animal care, disease management, and sustainable agriculture.”

In her installation address delivered on Monday 9 June 2025, Prof Hester C. Klopper, Vice-Chancellor and Principal of the UFS, highlighted the importance of this development, noting that it will position the university as a key contributor to veterinary science education in South Africa. "The establishment of a veterinary science programme at the UFS reflects our commitment to transdisciplinary research and addressing national priorities through innovation in higher education. This initiative not only strengthens our role in advancing food security, animal health, and sustainable agriculture, but also positions the UFS as a pivotal contributor to the continent’s development goals in these critical sectors."

This move comes in direct response to the country’s pressing need for more veterinary professionals, a shortage that poses risks to food security, animal welfare, public health, and agricultural productivity.

According to a report by the Western Cape Government (South Africa is Bleeding Veterinarians, February 2023), South Africa has only 60 to 70 veterinarians per million people – far below the international norm of 200 to 400 per million. This critical gap underscores the urgency of expanding veterinary education and training opportunities.

“This initiative directly addresses a national priority while aligning with continental and global aspirations towards sustainable development – especially in the areas of modern agriculture, food security, and environmental sustainability,” says Dr Nalize Scheepers from the Department of Sustainable Food Systems and Development.

 

Building a foundation for veterinary excellence

Although still in the early stages, the project has received in-principle approval from the Minister of Higher Education and Training, the Department of Agriculture (DoA), the Department of Higher Education and Training (DHET), and the South African Veterinary Council (SAVC).

The university has been exploring the feasibility of this programme for the past five years, involving consultations with various stakeholders in the higher education and veterinary sectors. "As a public higher education institution, we are subject to national regulation and will confirm commencement dates once final approval and accreditation of the qualification are secured," says Dr Scheepers.

As part of this initiative, a veterinary academic hospital is planned on the South Campus. “The facility will feature clinical training facilities – providing students with supervised, hands-on experience in animal diagnosis, surgery, and treatment; public veterinary services – offering essential care to local farmers, livestock owners, and pet owners in the surrounding communities; and research support – enabling applied research in critical areas such as animal health, epidemiology, and public health,” says Prof van Niekerk.

Beyond supporting academic excellence, the planned hospital will play a vital role in serving the wider agricultural community. “The hospital will address the urgent shortage of veterinary services in the region and contribute to the province’s animal health and food security goals,” he adds.

Initially, the BVSc degree will be offered within the Faculty of Natural and Agricultural Sciences, with plans to establish a dedicated School of Veterinary Science as the programme develops. The initiative also supports the UFS One Health Initiative, creating broad opportunities for research and development.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept